Can I Take Quercetin with Tadalafil (Generic)?

How Tadalafil Is Metabolized and Why That Matters

Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor approved by the FDA for erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension at oral doses ranging from 2.5 mg daily to 20 mg as needed. The drug is cleared almost entirely through hepatic oxidation by the CYP3A4 enzyme, with a mean terminal half-life of approximately 17.5 hours in healthy adults. Any compound that slows CYP3A4 activity will extend that half-life and raise peak plasma concentrations.

The CYP3A4 Pathway in Detail

The FDA's prescribing information for tadalafil (NDA 021368) states explicitly: "tadalafil is predominantly metabolised by CYP3A4. A potent inhibitor of CYP3A4, such as ketoconazole, increased the AUC of tadalafil 2-fold." [1] That 2-fold increase from a potent inhibitor sets the ceiling for comparison. Quercetin is not ketoconazole, but the comparison is instructive for understanding the direction of the risk.

What Happens When Clearance Slows

When CYP3A4 is partially blocked, tadalafil accumulates. Higher plasma concentrations amplify both the therapeutic effect (smooth muscle relaxation in penile vasculature and the bladder neck) and the adverse effect profile (systemic vasodilation, headache, back pain, flushing). For patients on daily 2.5 mg or 5 mg doses prescribed for BPH or continuous ED management, even a modest rise in exposure may push drug levels into a range that was never intended.

What Quercetin Does to CYP3A4

Quercetin is a flavonoid found in onions, apples, capers, and red wine, and it is widely sold in supplement form at doses of 250 mg to 1,000 mg per day. It has genuine biological activity. In vitro studies consistently show that quercetin inhibits CYP3A4, with IC50 values in the range of 10 to 40 µM depending on the substrate and assay method. [2]

In Vitro Evidence

A 2002 study published in Drug Metabolism and Disposition examined the inhibitory effects of flavonoids on human CYP3A4 activity using midazolam as a probe substrate. Quercetin produced concentration-dependent inhibition. [2] In vitro data do not always translate linearly to clinical effect, but they do establish mechanism.

Clinical Pharmacokinetic Data

A more directly relevant investigation involved quercetin co-administration with felodipine, another CYP3A4-dependent cardiovascular drug. A randomized crossover trial (N=12) published in the European Journal of Clinical Pharmacology found that 500 mg quercetin increased felodipine AUC by roughly 16% and maximum plasma concentration (Cmax) by approximately 20%, with corresponding blood pressure changes. [3] Felodipine and tadalafil share CYP3A4 as the primary clearance route, making this the closest available clinical analog.

Quercetin as a P-glycoprotein Inhibitor

Beyond CYP3A4, quercetin also inhibits P-glycoprotein (P-gp), an efflux transporter that limits intestinal absorption of many drugs. Tadalafil is a P-gp substrate to a modest degree. P-gp inhibition by quercetin could increase the fraction of an oral tadalafil dose that enters systemic circulation, compounding the CYP3A4 effect. A review in Molecular Nutrition and Food Research documented quercetin's P-gp inhibitory activity across multiple in vitro and animal models. [4]

Is There a Pharmacodynamic Interaction Too?

The metabolic interaction is the primary concern, but a pharmacodynamic layer exists as well.

Quercetin's Vasodilatory Properties

Quercetin has direct vasorelaxant effects. A meta-analysis of 7 randomized controlled trials (N=587) published in the Journal of the American Heart Association in 2016 found that quercetin supplementation reduced systolic blood pressure by a mean of 3.04 mmHg (P<0.001) and diastolic blood pressure by 2.63 mmHg (P<0.001). [5] Tadalafil produces dose-dependent vasodilation through PDE5 inhibition. Combining two agents that both lower blood pressure through different mechanisms creates additive hypotensive potential.

Clinical Significance at Different Tadalafil Doses

At tadalafil 2.5 mg daily, the hemodynamic effect is modest and the safety margin is relatively wide. At tadalafil 20 mg taken acutely for ED, the vasodilatory effect is substantially larger, and adding quercetin-driven blood pressure lowering on the same day becomes more clinically meaningful. Patients who also take alpha-blockers (e.g., tamsulosin for BPH) face a triple vasodilatory stack that has led to symptomatic hypotension episodes documented in pharmacovigilance reports. [1]

Who Is Most at Risk?

Not every person who takes quercetin with tadalafil will experience a problem. Several patient-specific factors raise the risk level.

High-Risk Patient Profiles

Patients most likely to experience a meaningful interaction include:

• Anyone taking tadalafil 20 mg on demand and consuming high-dose quercetin (500 to 1,000 mg) within the same 24-hour window
• Patients on concomitant alpha-blockers or antihypertensive agents
• Older adults (age 65+) whose hepatic CYP3A4 activity is already somewhat reduced
• Patients with mild hepatic impairment (Child-Pugh Class A or B), since tadalafil AUC is already elevated in this group [1]
• Anyone with a history of orthostatic hypotension

Lower-Risk Scenarios

A patient taking tadalafil 2.5 mg daily who consumes dietary quercetin through normal food intake (roughly 10 to 30 mg/day from a mixed diet) is unlikely to experience a clinically significant interaction. The concern scales with the supplement dose, not background dietary intake.

Dose-Separation Windows: What the Evidence Shows

A formal pharmacokinetic study pairing tadalafil with quercetin at clinically used doses has not been published as of mid-2025. In the absence of that specific data, the separation window recommendation is derived from quercetin's known pharmacokinetics. Quercetin is absorbed and reaches peak plasma concentrations within 1 to 2 hours of an oral dose, and its plasma half-life after absorption is approximately 3.5 to 7 hours depending on the formulation. [6]

A Practical Separation Framework

Based on these pharmacokinetic parameters, a reasonable working framework for providers is:

1. Acute tadalafil dosing (10 to 20 mg on demand): Avoid quercetin supplements for at least 12 hours before and 24 hours after the tadalafil dose, covering approximately 3 to 4 half-lives of quercetin.
2. Daily low-dose tadalafil (2.5 to 5 mg): Continuous dosing means there is no clean separation window. The decision becomes whether the supplement provides sufficient benefit to justify continuous co-exposure. That decision belongs to the prescriber.
3. Dietary quercetin only: No adjustment needed. Background dietary intake is unlikely to inhibit CYP3A4 to a clinically significant degree.

This framework has not been validated in a prospective trial. It represents a conservative extrapolation from available pharmacokinetic data and should be reviewed by the prescriber managing the patient's tadalafil regimen.

Monitoring and Warning Signs

If a patient and prescriber decide to continue both agents, structured monitoring is appropriate.

Blood Pressure Tracking

Home blood pressure monitoring, with readings taken at the same time of day, provides a practical safety check. A sustained drop in systolic pressure exceeding 10 mmHg compared to baseline warrants a medication review. The American Heart Association recommends a validated upper-arm cuff device for home monitoring. [7]

Symptoms to Watch For

Patients should stop quercetin and contact their prescriber if they experience:

• Dizziness or lightheadedness, especially on standing
• Flushing significantly worse than usual on tadalafil
• Headache lasting more than 4 hours after a tadalafil dose
• A sustained or painful erection lasting more than 2 hours (priapism risk)
• Sudden hearing changes or visual disturbances, which though rare have been associated with PDE5 inhibitor use [1]

What to Tell Your Prescriber

Transparency is the single most effective safety strategy. Patients often do not mention supplements because they assume natural products are automatically safe alongside prescription drugs. A 2017 JAMA Internal Medicine analysis estimated that approximately 34% of U.S. Adults using prescription medications concurrently use supplements, and fewer than 32% disclose this to their physician. [8]

Questions to Bring to the Appointment

Bring the quercetin product label (including dose per serving) and ask your prescriber:

• "Does quercetin at this dose affect how my tadalafil is cleared?"
• "Should I temporarily stop quercetin on the days I use tadalafil 20 mg?"
• "Do I need a lower tadalafil dose if I continue the supplement daily?"

Prescriber Considerations

For clinicians: the Natural Medicines database (formerly Natural Standard) rates the quercetin-tadalafil combination as a "moderate" interaction based on CYP3A4 and P-gp inhibition, recommending caution and possible tadalafil dose reduction if co-use is unavoidable. The FDA's prescribing label for tadalafil notes that even moderate CYP3A4 inhibitors (e.g., erythromycin at steady state) increased tadalafil AUC by approximately 182%, reinforcing that partial inhibition still carries real clinical weight. [1]

Alternatives to Quercetin Worth Discussing

If the primary reason for quercetin use is general antioxidant support or cardiovascular health, several alternatives have no known interaction with CYP3A4 or PDE5 inhibitors.

Lower-Interaction Options

• Vitamin C (ascorbic acid): Not a CYP3A4 inhibitor at standard supplemental doses. A Cochrane review of 29 trials supports modest blood pressure lowering at 500 mg/day but without the drug interaction profile of quercetin. [9]
• Magnesium glycinate: Supports vascular smooth muscle function through mechanisms unrelated to CYP enzymes. No known pharmacokinetic interaction with tadalafil.
• Coenzyme Q10 (CoQ10): Widely used for cardiovascular support. A meta-analysis in the Journal of Human Hypertension (N=12 trials) showed CoQ10 reduced systolic BP by 11 to 17 mmHg in some populations, but there is no documented CYP3A4 inhibition at standard doses. [10]

Switching supplements entirely may not be necessary. The goal is an informed decision made with the prescriber, not automatic avoidance.

Regulatory and Labeling Context

Tadalafil's FDA-approved labeling (revised 2018) contains explicit drug interaction guidance for CYP3A4 inhibitors but does not list quercetin by name, because quercetin entered widespread supplement use largely after major PDE5 inhibitor drug interaction studies were completed. [1] The omission does not mean safety has been confirmed. It means the specific combination has not been formally studied in a randomized pharmacokinetic trial.

The FDA's guidance framework for drug-supplement interactions places the burden of proof on the supplement manufacturer, not the drug manufacturer. Most quercetin products carry no interaction warning on their label. Consumers and clinicians should not interpret that silence as a safety signal.

Summary of the Interaction by Tadalafil Dose

| Tadalafil Dose | Regimen | Quercetin Risk Level | Suggested Action | |---|---|---|---| | 2.5 mg | Daily (BPH/ED) | Moderate | Prescriber review; BP monitoring | | 5 mg | Daily (BPH/ED) | Moderate | Prescriber review; BP monitoring | | 10 mg | As needed (ED) | Moderate-High | Avoid quercetin 12 h before / 24 h after | | 20 mg | As needed (ED) | High | Strong caution; separation or discontinue quercetin | | 20 mg | Pulmonary HTN | High | Specialist review required |

Risk classifications are based on pharmacokinetic extrapolation, not prospective clinical trial data.